Andrew Bindman named new AHRQ director

Andrew Bindman, MD, has been named director of the U.S. Agency for Healthcare Research and Quality (AHRQ), replacing Sharon B. Arnold, PhD, who has served as AHRQ’s Acting Director since the departure of Richard Kronick, PhD.

“As AHRQ Director, Dr. Bindman will drive the Agency’s three core missions of producing research and evidence to improve the quality and safety of health care and the functioning of the health care system, producing tools, and training materials to make sure that evidence is understood and used, and investing in data and measures used by providers, patients, and policymakers,” said Health and Human Services Secretary Sylvia M. Burwell.

Bindman has been practicing, teaching and conducting health sciences research at the Zuckerberg San Francisco General Hospital and Trauma Center for more than 30 years, as well as being a professor an affiliated faculty member within the Philip R. Lee Institute for Health Policy Studies at the University of California, San Francisco.

Bindman has gained national recognition by leading the development of an academic division focused on improving the care of distressed populations and a state-university partnership with California’s Medicaid program that promotes translating research into policy.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.